Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 11/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.38 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.38 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2944879 | 0.69 | ALDH1A1 (0.55) | ALDH1A1TSHRAOC3CA2CARM1 | |
| SCHEMBL4973158 | 0.69 | CYP19A1 (0.45) | CYP19A1ALDH1A1TSHRAOC3CYP2C19 | |
| SCHEMBL3271148 | 0.68 | TSHR (0.60) | ALDH1A1TSHRAOC3CA2CARM1 | |
| SCHEMBL134524 | 0.68 | TSHR (0.60) | ALDH1A1TSHRAOC3CA2CARM1 | |
| SCHEMBL2389512 | 0.67 | SIGMAR1 (0.47) | ALDH1A1TSHRCA2CYP2C19 | |
| Bromide SCHEMBL11212819 | 0.66 | CNR2 (0.58) | ALDH1A1TSHRAOC3CA2CARM1 | |
| Hydrochloric Acid SCHEMBL2137949 | 0.66 | CNR2 (0.58) | ALDH1A1TSHRAOC3CA2CARM1 | |
| Ammonia Solution, Strong SCHEMBL1348044 | 0.66 | CNR2 (0.58) | ALDH1A1TSHRAOC3CA2CARM1 | |
| SCHEMBL12049793 | 0.66 | CNR2 (0.64) | ALDH1A1TSHRAOC3CA2CARM1 | |
| Bromide SCHEMBL6760453 | 0.66 | CNR2 (0.58) | ALDH1A1TSHRAOC3CA2CARM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117835718-A | White light organic electroluminescent composition and application thereof | 深圳大学 | 2024-04-05 | — | — | CN | claimed |
| US-7504521-B2 | Methods for the preparation of pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB CO. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1732566-A2 | 6-AZAINDOLE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
| US-20060030708-A1 | Methods for the preparation of pyrrolotriazine compounds | BRISTOL-MYERS SQUIBB COMPANY | 2006-02-09 | — | — | US | disclosed |
| WO-2005097129-A2 | 6-AZAINDOLE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060030708-A1 | Methods for the preparation of pyrrolotriazine compounds | SDHB, SDHA, DHPS | CYP19A1 843/4885ALDH1A1 1708/4885TSHR 1541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.